

**Evgen Pharma plc**  
("Evgen" or "the Company" or "the Group")

**Notice of Full Year Results**

**26 May 2023** - Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases, will report its full year results for the financial year ended 31 March 2023 on Wednesday, 7 June 2023.

**Enquiries:**

**Evgen Pharma plc**  
Dr Huw Jones, CEO  
Richard Moulson, CFO

**Tel: +44 207 457 2020**  
[enquiries@evgen.com](mailto:enquiries@evgen.com)

**FinnCap (Nominated Advisor and Broker)**  
Geoff Nash / Teddy Whiley (Corporate Finance)  
Alice Lane/Nigel Birks (ECM)

**Tel: +44 20 7220 0500**

**Instinctif Partners**  
Melanie Toyne-Sewell / Rozi Morris / Adam Loudon

**Tel: +44 207 457 2020**  
[Evgen@Instinctif.com](mailto:Evgen@Instinctif.com)

**Notes to Editors**

**About Evgen Pharma plc**

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the highly biologically active compound sulforaphane and novel proprietary analogues based on sulforaphane.

The Company's lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer and recently a Phase 1b study of the Company's new enteric coated tablet formulation. The FDA has granted Orphan Drug status to SFX-01 in malignant glioma. SFX-01 will be investigated initially in this indication as an investigator sponsored study in the Netherlands.

The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and the US as part of the continuing strategy to build the scientific data for the compound. With respect to areas outside of oncology and inflammation, Evgen signed an out-licensing deal with JuvLife, the dietary products and functional foods division of Juvenescence Ltd, for the development of a naturally-sourced sulforaphane nutritional health supplement, stabilised using Evgen's Sulforadex® technology. More recently Evgen completed an out-licensing transaction with Stalica SA, a Swiss specialist company in neurodevelopmental disorders, commencing with autism spectrum disorder. The deal, if successful, will generate milestone payments of \$160.5m and a double-digit royalty on sales.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on AIM in London and trades under the ticker symbol EVG.

For further information, please visit: [www.evgen.com](http://www.evgen.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORSEWSUMEDSELI